| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 09/27/2001 | WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 09/27/2001 | WO2001009178A3 Human chaperone proteins |
| 09/27/2001 | WO2000041707A3 USE OF $i(LACTOBACILLUS SALIVARIUS) |
| 09/27/2001 | US20010025106 Antiallergens, bronchodilator |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025040 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene D4 antagonist or 5-lipoxygenase inhibitor or FLAP protein antagonist |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010025029 Novel stromelysin inhibitors |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024813 Human dendriac and brainiac-3 |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024653 Recombinant mycobacterium strain containing in its chromosome or on a plasmid a counterpart to a gene (which has been deactivated) in the wild type mycobacterium coding for a protein necessary for biosynthesis of a purine or pyrimidine |
| 09/27/2001 | US20010024649 Topical treatment comprises an ester or amide lipophilic molecule capable of traversing the statum corneum and inducing immature dendritic cells to migrat to the draining lymphoid organ |
| 09/27/2001 | US20010024648 Four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effeftive immunosuppressants for the treatment of autoimmune diseases and prevent organ trasplant rejection |
| 09/27/2001 | DE10015006A1 Nahrungsmittel und Nahrungsergänzungsmittel mit kaltgepreßtem Traubenkernöl und/ oder Kernschrot Foods and dietary supplements with cold-pressed grape seed oil and / or crushed seeds |
| 09/27/2001 | DE10012370A1 Use of oil-in-water emulsion as vaccine adjuvant, particularly for influenza and pneumococcal vaccines, administered at different site from the vaccine |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404327A1 Lipopeptide adjuvants |
| 09/27/2001 | CA2404226A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 09/27/2001 | CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403808A1 Thiepino [3,2-b] dihydropyridines and related compositions and methods |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403558A1 Thrombin inhibitors |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403447A1 Peptide derivative |
| 09/27/2001 | CA2403436A1 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402636A1 Composition and method for the prevention and/or the treatment of allergy |
| 09/27/2001 | CA2402252A1 Salmonella vaccine materials and methods |
| 09/27/2001 | CA2401887A1 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2399695A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | CA2399028A1 Use of mia in immunotherapy |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136077A1 Preparations containing virus-like particles as immunopotentiators administered through the mucosa |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135494A2 Neuron-associated proteins |
| 09/26/2001 | EP1135486A1 RECOMBINANT SOLUBLE Fc RECEPTORS |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135481A1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 09/26/2001 | EP1135463A2 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
| 09/26/2001 | EP1135415A1 Humanized antibodies to gamma-interferon |
| 09/26/2001 | EP1135414A2 Allo and auto-reactive t-cell epitopes |
| 09/26/2001 | EP1135412A2 Tumor necrosis factor receptor homologue-1 (trh1) |
| 09/26/2001 | EP1135406A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 09/26/2001 | EP1135390A1 Methotrexate derivatives |
| 09/26/2001 | EP1135371A1 Beta-alanine derivatives as alpha 4 integrin inhibitors |
| 09/26/2001 | EP1135367A1 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135163A1 Topical compositions comprising ascomycins |
| 09/26/2001 | EP1135162A2 Ordered molecular presentation of antigens, method of preparation and use |
| 09/26/2001 | EP1135158A2 Enhanced vaccines |
| 09/26/2001 | EP1135152A1 A pharmaceutical composition comprising cyclosporin in a lipid carrier |
| 09/26/2001 | EP1135151A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/26/2001 | EP1135150A1 Self-emulsifying compositions for drugs poorly soluble in water |
| 09/26/2001 | EP1135143A1 Immunomodulatory methods using carbohydrate antigens |
| 09/26/2001 | EP1135123A1 Use of isatin derivatives as ion channel activating agents |
| 09/26/2001 | EP1135107A1 Utilisation of capsules containing one or more antigenic substances for the prevention and/or treatment of autoimmune diseases |
| 09/26/2001 | EP0909271B1 Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation |
| 09/26/2001 | EP0804581B1 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
| 09/26/2001 | EP0775141B1 Phenyl xanthine derivatives |
| 09/26/2001 | EP0626968B1 Piperidinyl thiacyclic derivatives |
| 09/26/2001 | CN1314948A Targeted adenovirus vectors for delivery of heterologous genes |
| 09/26/2001 | CN1314893A IL-8 receptor antanonists |
| 09/26/2001 | CN1314385A New polypeptide-prostatic specific membrane antigen 9 and polynucleotide for coding such polypeptide |
| 09/26/2001 | CN1314379A New polypeptide-human microtubulin folding facto4 C 13 and polynucleotide for coding such polypeptide |
| 09/26/2001 | CN1314162A Lupus pill |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |
| 09/26/2001 | CN1071759C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and use thereof |
| 09/25/2001 | US6294654 Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region |
| 09/25/2001 | US6294574 Compounds and methods for the treatment of inflammatory and immune disorders |
| 09/25/2001 | US6294561 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/25/2001 | US6294556 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/25/2001 | US6294546 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/25/2001 | US6294541 Purine derivatives having phosphodiesterase IV inhibition activity |
| 09/25/2001 | US6294525 Reverse-turn mimetics and methods relating thereto |
| 09/25/2001 | US6294378 Method and reagents for genetic immunization |
| 09/25/2001 | US6294350 Methods for treating fibroproliferative diseases |
| 09/25/2001 | US6294347 Human FCγ receptor III |
| 09/25/2001 | US6294322 Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| 09/25/2001 | US6294177 Particularly useful in the treatment of mastitis. |
| 09/25/2001 | US6294175 Compounds |
| 09/25/2001 | US6294171 Methods for treating disease states comprising administration of low levels of antibodies |
| 09/25/2001 | CA2214601C Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
| 09/20/2001 | WO2001069253A2 3d model of an fc epsilon receptor alpha chain-ige fc region complex |
| 09/20/2001 | WO2001069240A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | WO2001068861A2 THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |